title: [Safety evaluation of anticancer drugs circuit in a regional hospital in Tunisia].
abstract: BACKGROUND
  Nowadays, the circuit of drugs is a plague. This situation may cause serious harm to patients. In this context, we conducted a study with the aim to describe and evaluate the circuit of anticancer drugs in a Tunisian regional hospital.
  
  
  METHODS
  This is an evaluative study of the risk of anticancer drugs, conducted over a period of 15 days during the year 2014 in the Department of Cancer Research of the Regional Hospital of Gafsa (Tunisia). The evaluation method is based on that conducted by the project "SECURIMED" and developed by the Coordination Committee of the Clinical Evaluation and Quality in Aquitaine (CCECQA) in France.
  
  
  RESULTS
  In our study, the observation of anticancer drugs circuit has revealed some deficiencies. We noted that the roles of the various actors are subject sometimes to tasks shifting, which may sometimes be dangerous. The study also revealed a lack and an inadequacy with the standards in terms of the necessary equipment for the preparation of the anticancer drugs.
  
  
  CONCLUSIONS
  Securing drugs circuit should be a priority included in all national processes and shared by all stakeholders to achieve a premium goal: the quality of care and patient safety.
authors.affiliation: Laboratoire de Recherche « LR12ES03 », Département de Médecine Familiale et Communautaire, Faculté de Médecine Ibn El Jazzar Sousse, Université de Sousse,Tunisie.
authors.forename: Jihène
authors.initials: J
authors.lastname: Sahli
authors.affiliation: Laboratoire de Recherche « LR12ES03 », Département de Médecine Familiale et Communautaire, Faculté de Médecine Ibn El Jazzar Sousse, Université de Sousse,Tunisie.
authors.forename: Meriam
authors.initials: M
authors.lastname: El Ghardallou
authors.affiliation: Laboratoire de Recherche « LR12ES03 », Département de Médecine Familiale et Communautaire, Faculté de Médecine Ibn El Jazzar Sousse, Université de Sousse,Tunisie.
authors.forename: Iheb
authors.initials: I
authors.lastname: Bougmiza
authors.affiliation: Service de Carcinologie, Hôpital Régional de Gafsa, Tunisie.
authors.forename: Besma
authors.initials: B
authors.lastname: Henchiri
authors.affiliation: Laboratoire de Recherche « LR12ES03 », Département de Médecine Familiale et Communautaire, Faculté de Médecine Ibn El Jazzar Sousse, Université de Sousse,Tunisie.
authors.forename: Manel
authors.initials: M
authors.lastname: Limam
authors.affiliation: Service de Carcinologie, Hôpital Régional de Gafsa, Tunisie.
authors.forename: Rim
authors.initials: R
authors.lastname: Mejdoub
authors.affiliation: Laboratoire de Recherche « LR12ES03 », Département de Médecine Familiale et Communautaire, Faculté de Médecine Ibn El Jazzar Sousse, Université de Sousse,Tunisie.
authors.forename: Ali
authors.initials: A
authors.lastname: Mtiraoui
authors.affiliation: Laboratoire de Recherche « LR12ES03 », Département de Médecine Familiale et Communautaire, Faculté de Médecine Ibn El Jazzar Sousse, Université de Sousse,Tunisie.
authors.forename: Thouraya
authors.initials: T
authors.lastname: Ajmi
mesh_terms: D000970:Antineoplastic Agents / Q000009:adverse effects*; D004339:Drug Compounding / Q000379:methods*; D004867:Equipment Design; D005260:Female; D006761:Hospitals; D006801:Humans; D008297:Male; D016273:Occupational Exposure / Q000032:analysis*; D014416:Tunisia
chemical_list: D000970:Antineoplastic Agents
keywords: Risk management; anticancer drugs; patient safety